Table 1

Patient demographics and baseline disease characteristics

Embedded Image
  • All groups are based on tofacitinib exposure data (not tofacitinib patient-level data).

  • *Average dosing was based on average daily dose: patients receiving <15 mg/day were assigned to the 5 mg twice daily group; patients receiving ≥15 mg/day were assigned to the 10 mg twice daily group.

  • †Constant dosage without prior exposure to another tofacitinib dose or adalimumab during the study; patients who switched doses were not included in this group.

  • ‡Most common DMARDs are listed.

  • BMI, body mass index; COPD, chronic obstructive pulmonary disease; DAS28-4(ESR), disease activity score in 28 joints, erythrocyte sedimentation rate; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; TB, tuberculosis; TNFi, tumour necrosis factor inhibitor.